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Abstract
The Sleeping Beauty (SB) and piggyBac (PB) DNA transposons represent an emerging new gene delivery
technology, potentially suitable for human gene therapy applications. Previous studies pointed to important
differences between these transposon systems, depending on the cell types examined and the methodologies
applied. However, efficiencies cannot always be compared because of differences in applications. In addition,
‘‘overproduction inhibition,’’ a phenomenon believed to be a characteristic of DNA transposons, can re-
markably reduce the overall transgenic rate, emphasizing the importance of transposase dose applied. There-
fore, because of lack of comprehensive analysis, researchers are forced to optimize the technology for their own
‘‘in-house’’ platforms. In this study, we investigated the transposition of several SB (SB11, SB32, SB100X) and
PB (mPB and hyPB) variants in various cell types at three levels: comparing the excision efficiency of the
reaction by real-time PCR, testing the overall transgenic rate by detecting cells with stable integrations, and
determining the average copy number when using different transposon systems and conditions. We concluded
that high excision activity is not always followed by a higher transgenic rate, as exemplified by the hyperactive
transposases, indicating that the excision and the integration steps of transposition are not strongly coupled as
previously thought. In general, all levels of transposition show remarkable differences depending on the
transposase used and cell lines examined, being the least efficient in human embryonic stem cells (hESCs). In
spite of the comparably low activity in those special cell types, the hyperactive SB100X and hyPB systems
could be used in hESCs with similar transgenic efficiency and with reasonably low (2–3) transgene copy
numbers, indicating their potential applicability for gene therapy purposes in the future.
Introduction
Transposons were first exclusively considered to begenomic parasites, placing a heavy burden on the host
genome. Later it was revealed that these mobile elements
have played active roles in shaping the genetic materials of
organisms (Kazazian, 2004; Feschotte and Pritham, 2007;
Goodier and Kazazian, 2008), and additional studies further
supported the idea that transposon activity could have a
positive impact during evolution even in higher eukaryotic
organisms (Singer et al., 2010; Shen et al., 2011). After
cloning and isolating active elements from various sources,
transposons have been used as molecular tools for genetic
experiments, including mutagenesis screens or transgenesis
experiments. DNA transposons are especially favorable for
such purposes, mainly because most of them are transposed
by a nonreplicative ‘‘cut and paste’’ mechanism (Ivics and
Izsva´k, 2004, 2006). For a long time, however, no DNA
transposons were known to be active in vertebrates, which
also limited human gene delivery and gene therapy application
by these molecular devices. This burden was lifted with the
‘‘resurrection’’ of the artificial transposon Sleeping Beauty
(SB), which can actively transpose in all vertebrate genomes
tested, including human cells (Ivics et al., 1997). Since then,
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various other transposons of several species have been shown
to be active in vertebrates (Miskey et al., 2003; Ding et al.,
2005; Balciunas et al., 2006). In addition, tremendous efforts
have been made to develop hyperactive transposase versions
(Zayed et al., 2004; Baus et al., 2005; Pledger and Coates,
2005) and with the development of the SB100X system
(Ma´te´s et al., 2009), transposon-based gene delivery became
a rational alternative to virus-based applications. Indeed, a
clinical trial has already been initiated using the SB system
(Williams, 2008).
At present, the most efficient and therefore the most
widely used transposon-based applications are the SB, pig-
gyBac (PB), and Tol2 systems, the latter two representing
naturally active transposons derived from the cabbage
looper moth (Trichoplusia ni) (Ding et al., 2005) and the
medaka fish (Balciunas et al., 2006) genomes, respectively.
All have high transgenic potential and can mobilize large
cargos (Rostovskaya et al., 2012; Wang et al., 2014), which
is a considerable factor as compared with viral packaging
systems. For safety considerations in gene therapy, SB
seems to be the most ideal system because of its favorable
integration profile: there is no obvious preference at the
genomic level, and therefore the delivered transgene is in-
tegrated randomly, lowering the risk of undesirable inser-
tional mutagenesis (Galvan et al., 2009; Grabundzija et al.,
2010; Izsva´k et al., 2010; Meir et al., 2011; Burnight et al.,
2012; M.A. Li et al., 2013). On the other hand, the clear
advantage of the PB system comes when the traceless re-
moval of the delivered transgene is favorable, as exempli-
fied by removal of the reprogramming cassettes after the
generation of induced pluripotent stem cells from somatic
cells (Kaji et al., 2009; Woltjen et al., 2009; Yusa et al.,
2009). In addition, this genetic manipulation is further en-
hanced with the development of an integration-deficient PB
transposase mutant (X. Li et al., 2013). Nevertheless, there
are various other aspects (e.g., transgene copy numbers,
applications in difficult-to-transfect cell lines) that require
careful adjustments and considerations, especially when
developing future gene therapy methodologies, and novel
DNA transposons with defined integration profiles may also
be considered for such purposes (Kojima and Jurka, 2013).
There are only a few studies addressing systematic com-
parisons of available transposon-based systems, and they
often concentrate on a limited number of cell lines, mainly
tumor cell lines, that may not be representative for all cell
types or for in vivo applications (Grabundzija et al., 2010;
Huang et al., 2010; Doherty et al., 2012; Sharma et al.,
2012). Moreover, specific interactions of the transposase
proteins with endogenous cell type-specific factors may also
influence the overall outcome of transposition, an important
aspect that also requires further investigations. In this study,
we systematically analyzed SB and PB transposition from
several aspects: examining the excision efficiency of the
transposase as compared with the transgenic rate and copy
numbers, the overall end products of transposition. More-
over, we examined the phenomenon of overproduction in-
hibition (OI), a transposase dose-dependent inhibition of the
reaction, which is believed to be a general characteristic of
DNA transposons (Lohe and Hartl, 1996; Hartl et al., 1997;
Lampe et al., 1998; Wilson et al., 2005; Claeys Bouuaert
et al., 2013). We found that the choice of transgene, as well
as the promoter identity, may also have a strong impact on
the outcome of the assays. Besides investigating cultured cell
lines, we also addressed all the raised issues in a human
embryonic stem cell line, which represents a model system
for tissue differentiation studies and for regenerative medi-
cine investigations. The important finding of our investiga-
tions is that although the SB100X transposon system seemed
to be performing better in several respects in cultured cell
lines, embryonic stem cells seem to represent an equally less
permissive environment for both SB and PB transposons.
Our results underlie the importance of careful optimization
of transposon-based gene delivery in the targeted cell type,
from the choice of the delivered gene expression cassette,
through the careful selection of the transposase system, until
the thorough setup of the gene delivery protocol. With all
these details cautiously addressed, transposon-based gene
methodologies clearly represent promising new technologies
for future gene therapy applications.
Materials and Methods
Cell lines and maintenance
Human embryonic kidney cells (HEK-293) and HeLa
cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum, 1%
l-glutamine, and 1% penicillin–streptomycin (Life Tech-
nologies, Carlsbad, CA). The HUES9 embryonic stem cell
line (originally provided by D. Melton, Harvard University,
Cambridge, MA) was maintained essentially as described
previously, using cells from passage 35 (Apa´ti et al., 2008).
Plasmid constructs, transfection methods,
and transposition assays
Structures of the transposon plasmids used are shown in
b F1Fig. 1A. During the comparison studies, the exactly same
expression cassette sequences were cloned between the cor-
responding SB or PB inverted repeat sequences. Transposase
proteins were expressed from standard expression plasmids
under the control of the cytomegalovirus (CMV) promoter;
transposase levels were checked by Western blotting. Dur-
ing the experiments, the following transposase protein var-
iants were used: for the SB system, the SB11, SB32, and
SB100X variants (Ma´te´s et al., 2009); for the PB system,
the mPB (Cadinanos and Bradley, 2007) and hyPB (Yusa
et al., 2011) variants.
All transfections were carried out in duplicate. For lipid-
based transfections, 2· 105 HEK-293 cells or 4· 105 HeLa
cells were seeded onto 12-well plates, and transfected with
FuGENE 6 or FuGENE HD reagent, respectively, according
to the manufacturer’s instructions (Roche, Basel, Switzer-
land). The next day, a maximum of 250 ng of transposon
plasmid was transfected with various amounts of transposase
plasmid, except when the transposon was rate limiting at 25 ng
(see Fig. 4C). All transfections were supplemented with
250 ng of pCMV-EGFP expression plasmid to control trans-
fection efficiencies. In every experiment, transfection cock-
tails were supplemented with pET-41 plasmid if necessary, to
ensure the same amount of total DNA in all reactions. At 48 hr
posttransfection, cells were harvested and counted; one-tenth
of them were analyzed with a FACSCalibur flow cytometer
(BD Biosciences, San Jose, CA) for green fluorescent protein
(GFP)-expressing cells to measure transfection efficiency. For
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FIG. 1. Transposon con-
structs and their application in
studying overproduction inhi-
bition on the level of excision of
DNA transposons. (A) Sche-
matic representation of the four
DNA transposons used. IRDR-
L/-R, inverted repeat-direct re-
peat sequences of SB and PB
transposons (left and right);
PGK, phosphoglycerate ki-
nase promoter; SV40, simian
virus 40 early promoter; CAG,
CMV enhancer–chicken b-
actin–rabbit b1-globin promot-
er; pA, polyadenylation signal.
(B–D) Transposase dose depen-
dence of excision efficiency:
when using lipid-based trans-
fection in (B) HEK-293 cells or
(C) HeLa cells, or (D) when
using nucleofection in HEK-293
cells. (E) Effect of the amount
of transposase on the excision
efficiency in the case of differ-
ent SB and PB variants in HEK-
293 cells.
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antibiotic selection, 1% of the transfected cells were seeded
onto cell culture Petri dishes, selected for 2 weeks with either
puromycin (1lg/ml; Sigma-Aldrich, St. Louis, MO) or G418
(600lg/ml; Sigma-Aldrich), and surviving cells were fixed
with methanol and stained with Giemsa (Sigma-Aldrich).
Colonies were quantified with a universal hood gel imager
model 75S, using Quantity One 4.4.0 software (Bio-Rad,
Hercules, CA). Transgenic rates were calculated from the
colony numbers, normalizing with the number of seeded cells
that was also normalized previously with transfection effi-
ciencies; transgenic rates are therefore defined as a percentage
of transfected cells.
In nucleofection experiments, 5 · 105 HEK-293 cells
were electroporated, using a Nucleofector kit V (Lonza
Group, Basel, Switzerland), according to the manufacturer’s
instructions. One microgram of transposon and various
amounts of transposase, supplemented with 1 lg of trans-
fection control plasmid, were transfected and seeded onto 6-
well plates. Electroporations were also filled up to equal
amount of DNA.AU2c HEK nucleofections were analyzed 48 hr
posttransfection for transfection efficiency by fluorescence-
activated cell sorting (FACS) and for transposon excision
efficiency by qPCR.
HUES9 cells were grown on feeder cells in 6-well plates
until confluency; then *2· 106 cells (one entire well per
nucleofection) were harvested for nucleofection with a human
stem cell Nucleofector kit 1 (Lonza Group). The same
amounts of DNA were applied as in HEK-293 cells, but be-
cause the transposon in these cases contained the CAG-EGFP-
expressing cassette, the transfection control plasmid could be
omitted. At 48 hr posttransfection, cells were analyzed by
FACS to determine transfection efficiency. At two later time
points (1 and 2 weeks later), the ratio of GFP-expressing
transgenic cells was also determined by FACS. Normalizing
this ratio with the transfection efficiency resulted in the ‘‘GFP
index,’’ which is proportional to the transgenic rate.
HEK-293 and HeLa transfection efficiencies were in the
range of 40–70%, and HUES9 electroporations were within
10–15% efficiencies, but in simultaneous transfection ex-
periments, deviations of transfection efficiencies showed
only a small range (3–8%) of alterations.
Quantitative real-time PCR measurements
All quantitative real-time PCR measurements were carried
out on a StepOnePlus real-time PCR system platform (Life
Technologies); SYBR green and TaqMan reactions were per-
formed according to the standard protocols. Data analysis
was done with StepOne software version 2.1 (Life Technolo-
gies) and relative quantifications were performed by the DDCt
method; error bars represents confidence intervals of 95%. To
quantify SB transposase-interacting factors at the mRNA level
by SYBR methodology, the following primer pairs were
used: for DNAPKcs (DNA-dependent protein kinase, catalytic
subunit): sense primer, 5¢-TTGAACACCATGTCCCAAGA;
antisense primer, 5¢-CTGACATTTTTGTCAGCCAATC; for
HMGB1 (high-mobility group protein B1): sense primer, 5¢-CA
TTGAGCTCCATAGAGACAGC; antisense primer, 5¢-AGG
ATCTCCTTTGCCCATGT; for Ku70: sense primer, 5¢-AGAG
TGAAGATGAGTTGACACCTTT; antisense primer, 5¢-CCA
AGAGATCTCGATCACTGCT; for Ku80: sense primer, 5¢-
CATCTGATGCTACCAGATTTTGA; antisense primer, 5¢-
TCCATGCTCACGATTAGTGC; for HSP90 (heat shock
protein 90, as endogenous control): sense primer, 5¢-TG
GATATCCCATTACTCTTTTTGTG; antisense primer, 5¢-
TTCTTTTTCTTCTTCTTTGTCTTCCT. Methods for de-
termining transposon excision efficiency and copy numbers
are described in the following sections in detail.
Quantifying transposon excision efficiency
After processing cells for transposition assays and for
measuring transfection efficiency at 48 hr posttransfection,
the remaining cells were used for the excision assay. Direct
comparisons of various transposases were carried out in
simultaneous experiments with similar transfection effi-
ciency values to exclude minor discrepancies due to high
transfection efficiency differences. Duplicated transfections
were pooled and plasmids were isolated from the cells,
using a modified protocol of the Qiagen plasmid miniprep
kit, applying 300ll of 1.2% sodium dodecyl sulfate (SDS)
supplemented with 50lg of proteinase K for the cell lysis
step and protein removal from the DNA. Ten nanograms of
each isolated plasmid DNA was used in a two-round nested
PCR assay in which primers were specific to the plasmid
backbone and resulted in a PCR product only from the ex-
cised and repaired plasmid copies due to large transposon
cassettes. First-round PCR primers were as follows: 5¢-
GCGAAAGGGGGATGTGCTGCAAGG, 5¢-TCTTTCCTG
CGTTATCCCCTGATTC. Fifteen cycles were done in a
20-ll reaction volume with 2 ·PCR master mix (Promega,
Madison, WI) and 200 nM primers. The first-round PCR
profile was as follows: 94C for 30 sec, 60C for 15 sec,
72C for 1min. Second-round PCR primers were as follows:
5¢-CAGCTGGCACGACAGGTTTCCCG, 5¢-CGATTAAG
TTGGGTAACGCCAGGG. A five-step fourfold dilution se-
ries (1024· ) was done from each first-round PCR and 5ll was
introduced to the second-round PCR, which was the real-time
PCR step, and it was carried out with 2·Power SYBR green
PCR master mix (Life Technologies) using 50nM concentra-
tions of primers in triplicate 20-ll reactions. Excision PCR was
normalized to the PCR from the ampicillin sequence, which
was present exclusively in the transposon donor constructs,
thus enabling quantification of the excised ratio of transposon
plasmids passed into the cell. bAU3In this way we could compare
excision efficiencies independent of transfection efficiency and
cell type. PCR primers for the ampicillin sequence were as
follows: 5¢-TTTGCTCACCCAGAAACGC, 5¢-AGTTGGCCG
CAGTGTTATCAC. Ampicillin-specific PCRs were done
similarly to the second-round excision PCR from the first-
round excision PCR product, using the same serial dilutions.
Efficiencies determined for all assays were in the range of
95–105%, so the DDCt method proved to be suitable for
quantification.
Determining transposon copy numbers
Average copy numbers of transgenic cell populations
were measured from transfected and selected cells. Con-
cerning the HEK-293 cell line, puromycin (1 lg/ml; Sigma-
Aldrich) selection was carried out for 3 weeks, and then
cells were harvested and duplicate transfections were
pooled. Genomic DNA was isolated by the standard phenol–
chloroform extraction method. For copy number mea-
surements, the amount of input DNA was 90 ng and the
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self-designed TaqMan assays were used as previously pub-
lished (Kolacsek et al., 2011). Briefly, specific assays were
applied for the SB inverted repeat-direct repeat sequence-left
region (SB-IRDR-L) transposon motif and the GFP-coding
sequence; the latter assay was used to determine PB trans-
poson copy numbers. Transposon-specific assays were nor-
malized to RPPH1 endogenous control assay, and genomic
DNA of cell clones with one transposon copy were also used
as reference samples (Kolacsek et al., 2011). Concerning
HUES9 cells, a GFP-expressing transposon cassette was used,
and therefore these transfections were sorted at 48 hr for the
GFP-expressing cells, and two additional sorts were carried
out for the selection of transgenic cells. Average copy num-
bers of cell populations were measured from these sorted cells
approximately 3 weeks after transfection.
Results
Cell type dependence of transposon excision rates:
SB100X never exhibits overproduction
inhibition at this level
The ‘‘cut and paste’’ mechanism of DNA transposons can
be divided into at least two well-defined steps: the excision
step from the donor locus and the integration step of the
transposon into the host genome. We attempted to charac-
terize these steps separately and to compare the PB and SB
variants from these aspects. To avoid variability resulting
from different DNA sequences, we cloned exactly the same
transgene cassette expressing the puromycin resistance gene
between the SB or PB inverted repeat (IR) sequences (Fig.
1A). The same amount of transposon-carrying plasmids was
transfected with variable amounts of the given transposase-
expressing plasmids into HEK-293 or HeLa cells by lipid-
based transfection. Excision efficiencies were measured by
real-time PCR-based quantification of the repaired donor
plasmids isolated from the cells 48 hr posttransfection. Ex-
cision PCR was normalized to the PCR of the ampicillin
sequence, which was exclusively present in the transposon
donor constructs, thus enabling determination of the ratio of
plasmids that underwent transposon excision to the total
amount of transposon-carrying plasmids passed into the cell.
In this way we can compare excision efficiencies in different
cell types. In HEK-293 cells, excision efficiencies increased
steadily with the amount of transposase for both the SB100X
and mPB systems, whereas in HeLa cells, mPB excision ac-
tivity showed a decline after a certain amount of transposase,
resembling the overproduction inhibition phenomenon (Fig.
1B and C). To further increase the transfection efficiency and
thereby the amount of expressed transposase in the cell, we
used nucleofection technology, which is known to achieve
higher transgene delivery efficiency (Aluigi et al., 2006). Using
this method, the mPB transposase indeed showed decreasing
excision efficiency even in HEK-293 cells with the increasing
amount of transposase, whereas the SB100X excision rate still
showed a positive correlation (Fig. 1D). In HEK-293 cells we
also examined the OI phenomenon for other, less active SB
versions (SB32 and SB11), as well as for a hyperactive PB
(hyPB) version in several experiments. None of the transpo-
sases showed OI when raising the transposase dose from 10:1
to 10:10, and hyPB showed the highest excision activity, ex-
ceeding that of SB100X (Fig. 1E). Similarly, no OI was de-
tected for the SB variants in HeLa cells (data not shown).
In comparing excision efficiencies between the two cell
lines at fixed transposon/transposase amounts, the HEK-293
cell line seemed the most permissive among all examined
systems ( b F2Fig. 2A). It is also notable that the hyperactive
transposases highly exceeds all other variants in terms of
excision efficiency, whereas from this point of view, mPB
showed efficiency comparable to different SB variants in
different cell lines: to SB32 in HEK-293 cells and to SB11
FIG. 2. Comparing the exci-
sion efficiencies of SB and PB
transposon systems in various
cell types. (A) Excision effi-
ciencies of various DNA trans-
posons in HEK-293 versus
HeLa cells at a fixed transposon-
to-transposase ratio. (B) Com-
parison of SB100X excision
efficiency in HEK-293 versus
HUES9 cells. (C) Transposase
dose dependence and compari-
son of excision efficiencies of
SB100X, mPB, and hyPB in a
human embryonic stem cell line,
HUES9.
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in HeLa cells. These correlations suggest that the cell type
dependence of mPB might not be similar to that of SB.
These results were independent of the transposon sequence
because similar excision results were obtained with different
transcription units such as CAG or CMV promoter-driven
EGFP expression cassettes (data not shown).
We also examined excision efficiency in the human
embryonic stem cell (hESC) line HUES9, another rele-
vant test system for gene therapy applications and tissue
differentiation models. Here, increasing the amount of
transposase also resulted in a higher excision rate of
SB100X, whereas the efficiency of mPB showed more of a
saturation-type reaction kinetic profile (Fig. 2C). How-
ever, for various transposase concentration points, mPB
and SB100X had similar excision efficiencies, although
these values were far below those measured in HEK-293
cells (Fig. 2B), or even in HeLa cells. When comparing
mPB with hyPB, the hyperactive version had higher ex-
cision efficiency but showed OI at a higher transposase
dose (Fig. 2C). To summarize this part of the study, the
excision step of DNA transposition showed strong cell
type dependence, with the hESCs being the least permis-
sive cell type for this event. In addition, the SB100X re-
action could not be saturated at this level, whereas under
the conditions applied the PB excision rate (both for mPB
and hyPB) was more sensitive to the amount of transpo-
sase present in the reaction.
Comparing transgenic rates of various transposon
systems in various cell types
To determine the stable integration of transgenes into the
host genomes, we performed colony-forming assays after
transfection and puromycin selection of cells. Transgenic
rates were determined in the same transfections as the ex-
cision assays, and were calculated from the number of de-
tected colonies defined as a percentage of seeded and also
transfected cells. The most prominent observation was that
high excision efficiencies did not correlate with higher
transgenic rates, and overproduction inhibition was also
detectable at this level. When examining the HEK-293 cell
line, overproduction inhibition could not be detected for
either the SB100X transposase or the mPB system ( b F3Fig. 3A).
In the HeLa cell line, transgenic rates of SB100X showed
more of a saturation curve when plotted as a function of
increasing transposase concentration (Fig. 3B), in contrast to
the strong OI results reported previously (Grabundzija et al.,
2010). On the other hand, mPB showed a tendency toward
slightly higher OI at higher transposase dose (especially at
10:20; see Fig. 3B), in agreement with the excision assay
FIG. 3. Transgenic rates of
SB and mPB systems and their
transposase dose dependence in
(A) HEK-293 cells and (B)
HeLa cells. (C) Transgenic rates
of different transposon systems
in the two cell lines at a fixed
transposon -to-transposase ratio.
(D) Effect of low and high
transposase doses on transgenic
rates in HEK-293 cells. Trans-
genic rates are defined as the
transgene-carrying cells, as a
percentage of total transfected
cells (see also Materials and
Methods). Error bars represent
SD values.
6 KOLACSEK ET AL.
HGTB-2013-149-ver9-Kolacsek_1P.3d 08/07/14 12:18pm Page 6
and also in line with some previous data (Grabundzija et al.,
2010) but not with others (Doherty et al., 2012).
We also compared the two cell types for overall trans-
genic rate at fixed transposon/transposase amounts (10:10).
HeLa cells showed the highest transgenic rates for hyper-
active transposases examined, with SB100X having the
highest values, and the SB32 variant exceeding the rate of
mPB (Fig. 3C). Nevertheless, the HeLa cell line is reported
to exhibit overproduction inhibition in terms of transgenic
rates for most transposases, although for the SB100X variant
our data partially contradict that previously reported, but
mPB showed OI at both levels, which was in agreement
with previous results (Grabundzija et al., 2010). An inter-
esting feature revealed was that in spite of the high excision
efficiencies in HEK-293 cells, transgenic rates for most
transposases were found to be significantly lower than in
HeLa cells (the only exception was the SB11 variant).
Moreover, SB32 seemed to be more efficient in HEK-293
cells than SB100X even at a low transposase dose (Fig. 3D),
and a high transposase dose of SB11 resulted in similar
transgenic efficiency, like SB100X. In addition, we could
not detect inhibition of less active SB variants at the
transgenic level (Fig. 3D), and the transgenic rate of SB11
increased to a similar extent as its excision activity when
raising the transposase dose (Fig. 1E vs. Fig. 3D). When
examining the PB systems, in spite of exhibiting the highest
excision activity in HEK-293 cells, the transgenic rate of the
hyPB variant was similar to that of mPB even at different
transposase doses, and it was lower than that of SB100X
( b F4Fig. 4A and B), which is not in agreement with some
previous results (Doherty et al., 2012). Taken together, our
results pointed out that despite the higher detectable exci-
sion rate of DNA transposons, HEK-293 cells seemed to be
less permissive for stable genomic integration of transgenes,
resulting in lower transgenic rates after transposition.
In previous studies, overproduction inhibition for SB
variants was found to be more prominent at low transposon
amounts, so we tested these conditions in our assay system
with the more susceptible HeLa cell line. However, we
could not see a decrease in transgenic rates with increasing
amount of transposase and even for less hyperactive vari-
ants; rather, a saturation-type curve could be derived when
plotting the data (Fig. 4C).
To determine whether the nature of the expression cas-
sette has any effect on the transgenic rate, we tested the
neomycin selection system in HeLa cells with different
promoters (CAG or SV40) at low transposon dose (Fig. 4D).
It turned out that they indeed influenced the kinetics of the
FIG. 4. Comparing the
transgenic rates of different
transposon systems. (A) Re-
presentative colony assays
and (B) transgenic rates of the
PB systems versus SB100X.
PB control: transfection car-
ried out with the PB transposon
cassette but without the trans-
posase; SB control: transfec-
tion carried out with the SB
transposon cassette and the
mutant SB transposase. (C)
Transposase dose dependence
of transgenic rates at low
transposon dose in HeLa cells.
(D) Measured dose depen-
dence of transgenic rates is
strongly influenced by the
transposon cassette sequences
and thereby the selection
methodology. Transgenic rates
are defined as the transgene-
carrying cells, as a percentage
of total transfected cells (see
also Materials and Methods).
Error bars represent SD values.
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transgenic rate, and slight inhibition was observed when
exactly the same expression cassette (SV40 promoter-driven
neomycin resistance gene) was used as in the previously
published study (Grabundzija et al., 2010). These results
emphasize the importance of the careful design of the ex-
pression cassette (e.g., choice of the promoter) carried by
the transposon as it can severely influence the outcome and
kinetics of the gene delivery and integration processes.
There are a number of proteins described to interact with
the SB transposase, most of which are involved in DNA re-
pair processes or in cell cycle regulation (Zayed et al., 2003;
Izsva´k et al., 2004; Walisko et al., 2006). As these proteins
could differ in their cell type-specific distribution and activ-
ity, we measured the mRNA expression levels of four SB-
interacting factors (DNAPKcs, HMGB1, Ku70, Ku80) in the
HeLa and HEK-293 cell lines. Contrary to our expectations,
the expression patterns of all examined factors were strikingly
similar in both cell lines (data not shown), so at least their
expression level differences cannot be attributed to the sharp
differences in excision efficiency and in transgenic rates.
Overproduction inhibition at the transgenic rateAU4c was also
examined in hESCs. However, puromycin selection cannot
be reliably applied to these cells as they express the ABCG2
membrane transporter protein, which can extrude the se-
lecting compound from the cells (Sarkadi et al., 2010).
Therefore, for these experiments we used a GFP-expressing
transposon cassette. We measured the transfected cell ratio
48 hr posttransfection via FACS, and the ratio of transgene-
expressing cells 1 and 2 weeks later. Normalizing the latter
with the transfection efficiency resulted in the GFP index,
which is proportional to the transgenic rate. SB100X
showed a decline in GFP index at a 10:20 transposon/
transposase dose in these cells (F5c Fig. 5A), which might be
attributable to overproduction inhibition that exhibits solely
in transgenic rate.AU5c Here again, excision efficiencies cannot
reliably predict the overall transposition rate, as the excision
rate of SB100X showed a continuous increase in this range
of transposase concentration (Fig. 2C). The GFP index of
mPB showed more of a saturation-type kinetic curve in
hESCs (data not shown), similar to what was measured for
its excision efficiency (Fig. 2C). Under conditions in which
SB100X and PB showed similar excision efficiency (10:10
ratio) we compared the SB and PB variants for the GFP
index (Fig. 5B and C). In these experiments lower activity
SB variants were notably less efficient for gene delivery in
hESCs compared with SB100X, whereas both mPB and
hyPB had higher transgenic rates than SB100X by 2 weeks
posttransfection (Fig. 5C), which is in line with some pre-
vious data (Yusa et al., 2011). These results indicate that
there are certain cell types in which the overall PB trans-
position rate can outweigh that of the SB100X system, and
hESCs seem to be one example of these.
Transgenic copy numbers: SB generally exceeds PB
A crucial issue in any gene delivery experiment is to
determine the stably integrated transgene copy numbers. In
one of the former comparative experiments, in which SB
variants and mPB were tested in HEK-293 cells at two
different transposase doses (10:1 and 10:10; see Figs. 1E
and 3D) we determined the average transposon copy num-
bers after 3 weeks of selection (F6c Fig. 6A). In general, mPB
transposition resulted in the lowest average copy numbers,
lower than expected on the basis of excision and the trans-
genic rate comparisons (Figs. 1E and 3D), a finding that was
in agreement with a previous study addressing copy number
issues in HeLa cells (Grabundzija et al., 2010). Similar re-
sults were obtained with the hyPB version: the copy num-
bers were comparable to that measured for the mPB version,
again showing a clear indication that the high excision ac-
tivity of a hyperactive transposase may not necessarily
FIG. 5. GFP indexes: the ratio of transfected cells that
retain transgene expression in the HUES9 cell line. (A) Dose
dependency of the GFP index when using SB100X, mea-
sured at two time points after transfection. (B) GFP indexes
at a fixed transposon-to-transposase ratio of different SB
variants versus the mPB transposon system. (C) GFP in-
dexes at a fixed transposon-to-transposase ratio of different
PB variants versus the SB100X transposon system.
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indicate higher transgenic rates and/or copy numbers. Using
a high amount of transposons with low transposase con-
centrations (10:1 in Fig. 6A), the SB variants produced high
copy numbers (‡10) after 3 weeks of selection, with
SB100X resulting in extreme copy numbers of even ‡ 40 in
some of our experiments. In this case, high copy numbers
seemed to be associated with the high excision efficiency of
SB100X. However, it again does not necessarily mean
higher transgenic rates because SB32 could exceed SB100X
in this aspect (Fig. 3D).
High transgene copy numbers are clearly unfavorable
when considering gene therapy applications because, among
other problems, it significantly increases the risk of inser-
tional mutagenesis. It also places a heavy burden on any
cellular genome, which is seen in experiments when trans-
genic cells were kept in culture for 6 weeks and the average
copy number dropped significantly. Our experiments with
HEK-293 cells indicate that average copy numbers ex-
ceeding 20 cannot be stably maintained in long-term culture.
The most effective way to avoid such high copy numbers is
to substantially lower the amount of transposon in the re-
action. This can result in physiologically more acceptable
copy numbers of 5–6 when using SB100X, without effec-
tively lowering the transgenic rate (Fig. 6B and C). The
same also works for the mPB transposase, lowering its copy
number from *3 to 1.
Considering hESCs, however, the copy number profiles of
DNA transposons were found to be different from the other
examined cell types. The mPB system produced the char-
acteristically low transgene copy numbers (*2–3) that was
observed in HEK-293 cells, whereas the SB100X transposase
did not result in such extreme copy numbers as in other cell
lines; both transposase systems resulted in an average copy
number of *2 in HUES9 cells. Just like for excision effi-
ciency and transgenic rates, this suggests that PB can work
efficiently in hESCs despite the fact that these cell types seem
to be less permissive for transgenic manipulations.
Discussion
The rationale behind our study was to carefully examine
the two most common and reportedly most efficient vector
systems, the Sleeping Beauty and piggyBac transposon ve-
hicles, in normal (HEK-293) and tumorous (HeLa) model
cells, as well as in human embryonic stem cells. We also
aimed to characterize aspects of the transposition reaction
that have not been investigated in detail so far: we compared
the excision efficiency of the transposases with their trans-
genic rates (the overall outcome of transposition), addressed
the presence of overproduction inhibition at both levels, and
also shed light on the connection between these properties
and the average transgene copy numbers resulting from
transposon-based gene delivery.
To examine the excision phase of transposition, we stud-
ied this reaction by a real-time PCR method using SYBR
green technology. As opposed to a previous study in which
TaqMan chemistry was used (Jin et al., 2011), the potential
occurrence of imprecise excision by the SB transposase (Liu
et al., 2004) prompted us to apply a method that was not
biased by the sequence variability of the repaired donor locus
after excision, so all possible excision events could be con-
fidently detected. Our studies revealed that transposon ex-
cision is strongly cell type dependent, indicating that certain
cell types represent a more permissive environment for the
reaction. In our experiments, the highest excision rates were
detected in HEK-293 cells, in which the level could be a
magnitude higher than in hESCs. An important finding was
that the selection for hyperactive transposases often results in
higher excision efficiency as exemplified by the SB100X and
hyPB variants. However, overproduction inhibition (Lohe
and Hartl, 1996; Hartl et al., 1997) may still affect the ex-
cision reaction in a cell type-dependent manner: hyPB was
sensitive to the amount of transposase in hESCs, whereas the
excision of SB100X could be saturated under the conditions
tested. The high excision efficiency of a hyperactive trans-
posase, on the other hand, is not necessarily accompanied by
FIG. 6. Copy numbers of DNA transposons in HEK-293
cells. (A) Copy numbers resulting from different transposon
systems at low versus high transposase dose. Limiting the
amount of transposon also influenced (B) copy numbers and
(C) transgenic rates when applying different DNA trans-
poson systems. Mut, control transfection/transposition with
a catalytically inactive SB transposase.
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higher transgenic rates or higher copy numbers: in spite of
the highest excision values, the transgenic rates measured in
HEK-293 cells were lower than in HeLa cells; moreover,
SB32 may achieve higher transgenic rates in certain cell
types than the hyperactive SB100X. Cell type-specific dif-
ferences may be due to different cellular defense mecha-
nisms and/or interacting factors. The higher number of
transgenic clones in HeLa cells may be related to its can-
cerous phenotype and its higher ‘‘genomic buffer’’ capacity
due to the higher number of chromosomes. An important
conclusion therefore is that testing the excision efficiency of
transposases is a good prescreen for activity; however, it may
not be representative of the overall transposition activity.
An important result of our study was that in human em-
bryonic stem cells much lower (one magnitude lower) ac-
tivity of the examined systems was detected, even at the
excision level of transposition. On the other hand, at this
lower level of activity, there did not seem to be a significant
difference between SB100X and the two PB variants, and
both mPB and hyPB seemed to outweigh SB100X in trans-
genic rates. This was also detected on investigating transgene
copy numbers: whereas SB100X delivered copy numbers
significantly lower as compared with values in other cultured
cell lines, use of the PB system resulted in the ‘‘expected’’
number of transgene copies. Nevertheless, we cannot rule out
that for the PB system, the more permissive environment in
embryonic stem cells is due to specific cell factors; this needs
further investigation.
In our experiments, another important result was that the
nature of the promoter and the transgene sequence, as well
as the nature of the selection method, might influence the
phenomenon of overproduction inhibition of the transgenic
rate. Changing only the promoter of the neomycin trans-
gene, the transposase dose–response curve showed different,
rather saturation-type kinetics in the same cell line. How-
ever, when the selection method was changed to puromycin
(the resistance gene driven by the housekeeping PGK pro-
moter) the curve changed significantly (Fig. 4D), with lower
transgenic rates and showing a constant increase with en-
zyme activity. These results point to the importance of and
need to optimize new transposon constructs, but also indi-
cate that increasing transposition efficiency might be
achieved by increasing the transposase concentration when
it is not contra-indicated (e.g., minimizing the probability of
transposase integration in gene therapy applications).
An important aspect of gene delivery is the transgene copy
numbers achieved by a given method. Mutagenesis screens
can favor higher copy numbers to maximize the hits, whereas
gene therapy applications typically favor low copy numbers
to avoid genotoxicity by high gene dose or the unwanted
burden of insertional mutagenesis. Our results clearly dem-
onstrate that high excision activity is not necessarily associ-
ated with increased copy numbers as hyperactive transposases
behave differently: as opposed to hyPB, SB100X can achieve
high copy numbers. It can be concluded that excision of DNA
transposons might not always be followed by integration,
which is more pronounced in the case of the hyPB version. It
is possible that for the PB system, the excision and integration
phases of transposition are kinetically more distinct than for
other DNA transposons. This could explain why the PB
transposase could be used to remove the previously integrated
transgenes (Kaji et al., 2009; Woltjen et al., 2009; Yusa et al.,
2009) and why an integration mutant PB with merely exci-
sion activity could be generated (X. Li et al., 2013). For the
SB100X variant, the key factor to manipulate copy numbers
is to change the amount of the transposon, rather than the
transposase (Fig. 6A and B). It is worth noting that the
transgenic rate will reflect the transposase ab ovo activity
only if the transposon amount is rate limiting (Figs. 3D and
6C), and this is exactly the case with gene delivery into
difficult-to-transfect cells; that is why hyperactive transposase
versions are substantially more efficient in these applications.
The sole disadvantage of low average copy number is that it
carries the possibility that transgenic rates may decrease even
further due to OI because inhibition will raise the number of
cells that will not receive even a single copy of transgene. In
the case of higher average copy number, inhibition will result
only in a decrease in average copy number but not in trans-
genic cell number. An alternative solution to the problem
could be achieved by a method published by Cai and col-
leagues (2014): they demonstrated that the hyPB transposase
embedded in a lentiviral Gag polypeptide could be used ef-
ficiently to generate single-copy clones while still keeping a
high average transgenic rate.
In this study, we demonstrated strong cell type differences
between SB and PB DNA transposons both at the excision
level and in transgenic rate of transposition. We could provide
additional data that the overproduction inhibition is not such a
widespread phenomenon as previously anticipated and that
careful experimental design could maximize the efficiency of
gene delivery. An important finding of our study is that
hyperactive DNA transposase versions seem to be selected
for high excision efficiency, which is not necessarily coupled
with either higher transgenic rate or increased transgene copy
number. Nevertheless, the hyperactive transposases are defi-
nitely the method of choice both for insertional mutagenesis
and for general gene delivery purposes. Our results also in-
dicate that in terms of efficiency, the PB system seemed to
outweigh SB100X in human embryonic stem cells, although
its reported nonrandom integration profile (Wilson et al.,
2007; Wang et al., 2008; Galvan et al., 2009; Liang et al.,
2009) should be considered when such experiments are de-
signed for gene therapy purposes.
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